Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan + Adebrelimab + Lenvatinib in 1L HER2+ or HER2-low Biliary Tract Cancer
NCT07670273Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in biliary tract cancer (BTC), sponsored by Peking Union Medical College Hospital. Started Apr 2026; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07670273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07670273.